gMG treatments show varied benefits across response measures

Approved and experimental targeted treatments for generalized myasthenia gravis (gMG) show different patterns of benefit across measures of treatment response, according to an indirect comparison analysis of clinical trial data.

Using mathematical models to account for differences in dosing schedules, researchers found that individual therapies differed in their maximum benefit, speed of response, and cumulative benefit on measures of daily function and muscle strength. Comparisons between different treatment classes also differed depending on which of these two measures was used.

The findings suggest that looking at several aspects of treatment response — rather than relying on a single measure at one time point — could provide a fuller picture of a therapy’s efficacy, help improve the design of clinical trials, and ultimately support more individualized treatment decisions.

The study, “Regimen-stratified Bayesian model-based meta-analysis of targeted biologics in generalised myasthenia gravis: efficacy comparison, mechanism-level class contrast, and endpoint sensitivity with model-informed trial design,” was published in Naunyn-Schmiedeberg’s Archives of Pharmacology.

Recommended Reading

Oct. 6, 2026 News by Lila Levinson, PhD

MGFA Session 2026: Repeat CAR T-cell care eases gMG for some

Indirect treatment comparison across trials can be complicated

gMG occurs when self-reactive antibodies mistakenly attack proteins important for nerve-cell communication, leading to symptoms such as muscle weakness and fatigue.

Several targeted therapies are already approved or in development for gMG. These include complement inhibitors, which block part of the immune system that contributes to gMG-related damage, and FcRn inhibitors, which lower levels of disease-causing antibodies in the bloodstream. Other approaches target immune cells or signaling pathways involved in antibody production.

Indirect treatment comparison across trials can be complicated by a number of factors, including dosing schedules. Some therapies are given continuously, while others are administered in cycles, meaning their effects may rise and fall over time and may not be fully captured at a single assessment.

Inn  this study, a team of researchers in India used mathematical models to account for differences in dosing schedules between nine targeted gMG therapies when indirectly comparing their efficacy based on data from placebo-controlled Phase 3 clinical trials.

The medications included:

• three approved complement inhibitors: Soliris (eculizumab), Ultomiris (ravulizumab-cwvz), and Zilbrysq (zilucoplan)
• four FcRn inhibitors: the approved therapies Vyvgart (efgartigimod alfa-fcab), Rystiggo (rozanolixizumab-noli), and Imaavy (nipocalimab-aahu), and the experimental treatment batoclimab
• the approved medication Uplizna (inebilizumab-cdon), which targets antibody-producing immune cells
• satralizumab, which blocks an immune signaling molecule involved in antibody production. Sold as Enspryng for treating another autoimmune disease, the medication was tested in gMG trials, but resulted in only small benefits, leading to the discontinuation of its development for gMG.

Recommended Reading

Sept. 30, 2026 News by Lindsey Shapiro, PhD

MGFA Session 2026: Single CAR T-cell therapy dose eases gMG up to 1.5 years

Vyvgart the fastest to produce clinically meaningful improvements

Treatment efficacy was assessed with the Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scales. MG-ADL is a patient-reported measure of the disease’s impact on everyday activities, while QMG is a clinician-assessed measure of muscle strength. Lower scores on either scale indicate less severe disease.

On MG-ADL, Zilbrysq showed the largest estimated maximum improvement, closely followed by batoclimab. On QMG, batoclimab showed the largest estimated maximum improvement, followed by Rystiggo and Vyvgart.

When treatments were grouped by how they work, FcRn inhibitors showed a greater estimated maximum improvement than complement inhibitors on QMG, but no clear difference emerged on MG-ADL. These findings suggest that treatment comparisons may differ depending on whether efficacy is assessed through patient-reported disease impact or clinician-measured muscle strength.

The treatments also differed in how quickly clinically meaningful improvements emerged. Vyvgart was estimated to be the fastest to produce such benefits on both scales. It was followed by Zilbrysq on MG-ADL and by batoclimab and Rystiggo on QMG.

Also, over 26 weeks (about six months), Zilbrysq showed the greatest cumulative improvement on MG-ADL, followed by Soliris and Vyvgart. On QMG, Vyvgart ranked highest, followed by batoclimab and Imaavy.

Real-world effectiveness studies will be essential to validate or refine the comparative rankings reported here.

The analysis also highlighted the importance of assessment timing for cyclical treatments. In simulated Rystiggo trials, the probability of detecting an MG-ADL treatment effect fell from 77% at week 12 to 65% at week 26 when only those individual time points were considered.

Considering improvement across the treatment period raised that probability to 94% to 95%, suggesting that assessment at a single time point could underestimate a cyclical treatment’s effects if it occurs when benefits have waned between treatment periods.

The researchers also examined how treatment comparisons changed when different aspects of efficacy, safety, tolerability, and convenience were given greater importance. Batoclimab had the highest overall score across these different scenarios. However, the relative performance of the other therapies varied depending on which treatment features were prioritized.

Because differences in patients’ initial features and background therapies across trials can influence the comparisons and limit how broadly the findings apply, “real-world effectiveness studies will be essential to validate or refine the comparative rankings reported here,” the team wrote.

Still, the analysis suggests that “a single efficacy-based ranking remains insufficient to guide treatment choice for an individual patient,” the researchers wrote. Combining different measures of treatment efficacy “with safety, tolerability and convenience data” may instead help tailor treatment decisions as gMG treatment options continue to expand.